Novo’s pioneering diabetes pill impresses in first big study

The world’s largest diabetes drugmaker, Novo Nordisk, on Thursday presented the first successful data from a large final-stage study of a pill it hopes will transform the diabetes market.

The oral form of the drug, known generically as semaglutide, is crucial for ensuring the group’s long-term growth, as price pressure mounts in a crowded market targeting the world’s 450 million diabetics.

The new medicine is a threat to Eli Lilly, a key rival in the multibillion-dollar diabetes market.

Leave a Reply

Your email address will not be published. Required fields are marked *